Immune checkpoint inhibitors (ICIs) are novel immunotherapy-based drugs that have
become increasingly popular in the treatment of lung cancer. Researchers have recognized …

Purpose To investigate the incidence of immune-related adverse events (irAEs) of immune
checkpoint inhibitor (ICI) therapy and to report the clinical features, management, and …

ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have improved prognosis in
advanced malignancies; however, they may be associated with extensive ocular immune …

Abstract Introduction Immune checkpoint inhibitors (ICIs) have become an important part of
the treatment of multiple cancers, especially for advanced melanoma and non-small cell …

Purpose Characterize ocular adverse events (oAEs) caused by immune checkpoint
inhibitors (ICIs). Methods Retrospective analysis of 41,674 cancer patients in the FDA …

Purpose To report the clinical features, severity, and management of ocular immune-related
adverse events (irAEs) in the setting of immune checkpoint inhibitor therapy for metastatic …

Ocular immune-related adverse events (IrAEs) associated with use of checkpoint inhibitors
(CPIs) in cancer therapeutics are relatively rare, occurring in approximately 1% of treated …

The increased use of targeted therapy and immune checkpoint inhibitors in cancers has
brought new hope of survival to patients with advanced tumors. However, increasing …

Immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte antigen 4 and
programmed cell death protein 1 receptor/ligand have revolutionized cancer treatment …

Objective Immune checkpoint inhibitors (ICIs) are novel cancer therapies that may be
associated with immune-related adverse events (IRAEs) and come to the attention of neuro …